etoposide
accord healthcare limited - etoposide - concentrate for soln for inf - 20 mg/ml - etoposide
vepesid 100 milligram capsules, soft
bristol-myers squibb (holdings) limited - etoposide - capsules, soft - 100 milligram - podophyllotoxin derivatives
vepesid 50 mg milligram capsule
bristol-myers squibb (holdings) limited - etoposide - capsule - 50 mg milligram - podophyllotoxin derivatives
etoposide 20 mg/ml concentrate for soln for inf
cipla (eu) limited - etoposide - concentrate for soln for inf - 20 mg/ml - podophyllotoxin derivatives - it is indicated in adults for the management of: resistant non-seminomatous testicular tumours in combination with other chemotherapeutic agents; small cell lung cancer, in combination with other chemotherapeutic agents; acute monoblastic leukaemia (aml m5) and acute myelomonoblastic leukaemia (aml m4) when standard induction therapy has failed (in combination with other chemotherapeutic agents).
etoposide 20mg/ml concentrate for solution for infusion (100mg/5ml)
accord healthcare limited - etoposide - concentrate for solution for infusion - etoposide 20 mg/ml - antineoplastic agents
etoposide 20mg/ml concentrate for solutionn for infusion (5ml vial)
fresenius kabi oncology plc - etoposide - concentrate for solution for infusion - etoposide 20 mg/ml - antineoplastic agents
etoposide 20mg/ml concentrate for solutionn for infusion (10ml vial)
fresenius kabi oncology plc - etoposide - concentrate for solution for infusion - etoposide 20 mg/ml - antineoplastic agents
etoposide 20mg/ml concentrate for solutionn for infusion (25ml vial)
fresenius kabi oncology plc - etoposide - concentrate for solution for infusion - etoposide 20 mg/ml - antineoplastic agents
etoposide 20mg/ml concentrate for solutionn for infusion (50ml vial)
fresenius kabi oncology plc - etoposide - concentrate for solution for infusion - etoposide 20 mg/ml - antineoplastic agents
eposin, concentrate for solution for infusion 20mg/ml
pharmachemie b.v. - etoposide, ph.eur. - concentrate for solution for infusion (to dilute). - 20mg/ml - podophyllotoxine derivatives - for the management of: - testicular tumours in combination with other chemotherapeutic agents - small cell lung cancer, in combination with other chemotherapeutic agents - monoblastic leukaemia (aml m5) and acute myelomonoblastic leukaemia (aml m4) when standard therapy has failed (in combination with other chemotherapeutic agents).